RESUMO
BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness. METHODS: EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated. RESULTS: Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin - placebo], -0.25 [95% CI, -0.58 to 0.09]; P=0.14) or HFpEF (adjusted mean treatment difference, -0.16 [95% CI, -0.60 to 0.29]; P=0.47]. Likewise, there were no changes in PCr/ATP during dobutamine stress in HFrEF (adjusted mean treatment difference, -0.13 [95% CI, -0.35 to 0.09]; P=0.23) or HFpEF (adjusted mean treatment difference, -0.22 [95% CI, -0.66 to 0.23]; P=0.32). No changes in serum metabolomics or levels of circulating ketone bodies were observed. CONCLUSIONS: In patients with either HFrEF or HFpEF, treatment with 10 mg of empagliflozin once daily for 12 weeks did not improve cardiac energetics or change circulating serum metabolites associated with energy metabolism when compared with placebo. Based on our results, it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03332212.
Assuntos
Insuficiência Cardíaca , Humanos , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Volume Sistólico , Função Ventricular Esquerda , Estudos Prospectivos , Dobutamina/farmacologia , Metabolismo Energético , Trifosfato de AdenosinaRESUMO
The purpose of this project report is to introduce the European "GOLIATH" project, a new research project which addresses one of the most urgent regulatory needs in the testing of endocrine-disrupting chemicals (EDCs), namely the lack of methods for testing EDCs that disrupt metabolism and metabolic functions. These chemicals collectively referred to as "metabolism disrupting compounds" (MDCs) are natural and anthropogenic chemicals that can promote metabolic changes that can ultimately result in obesity, diabetes, and/or fatty liver in humans. This project report introduces the main approaches of the project and provides a focused review of the evidence of metabolic disruption for selected EDCs. GOLIATH will generate the world's first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. GOLIATH will focus on the main cellular targets of metabolic disruption-hepatocytes, pancreatic endocrine cells, myocytes and adipocytes-and using an adverse outcome pathway (AOP) framework will provide key information on MDC-related mode of action by incorporating multi-omic analyses and translating results from in silico, in vitro, and in vivo models and assays to adverse metabolic health outcomes in humans at real-life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the Organisation for Economic Development (OECD) for test method (pre-)validation, IATA, and AOP development.
Assuntos
Diabetes Mellitus/epidemiologia , Disruptores Endócrinos/efeitos adversos , Fígado Gorduroso/epidemiologia , Obesidade/epidemiologia , Adipócitos/efeitos dos fármacos , Adipócitos/patologia , Diabetes Mellitus/induzido quimicamente , Diabetes Mellitus/prevenção & controle , Fígado Gorduroso/induzido quimicamente , Fígado Gorduroso/prevenção & controle , Humanos , Redes e Vias Metabólicas/efeitos dos fármacos , Obesidade/induzido quimicamente , Obesidade/prevenção & controle , Medição de RiscoRESUMO
Metabolic profiling can be used to assess the changes in biochemical profiles of soil communities living in contaminated sites. The term "community metabolomics" is proposed for the application of metabolomics techniques to the study of the entire community of a soil sample. The authors anticipate the present study to be a starting point for the use of this technique to assess how communities respond to factors such as pollution and climate change.
Assuntos
Monitoramento Ambiental/métodos , Metabolômica , Microbiologia do Solo , Aminoácidos/análise , Carboidratos/análise , Carbono/análise , Poluição Ambiental/análise , Concentração de Íons de Hidrogênio , Metais/análise , Mineração , Nucleotídeos/análise , Poluentes do Solo/análiseRESUMO
The effects of cadmium were assessed in the freshwater alga Chlamydomonas reinhardtii. Algae were exposed to concentrations of 0, 8.1 or 114.8 µM of cadmium and growth rates, gene transcription and metabolite profiles were examined after 48 and 72 h of exposure. In algae exposed to 8.1 µM Cd, several genes were differentially transcribed after 48 h but no adverse growth related effects were detected. A transient effect on both gene transcription patterns and metabolite profiles could be discerned after 48 h of exposure but the majority of these changes disappeared after 72 h. In contrast, all effects were more pronounced at the 114.8 µM cadmium exposure. Here growth was clearly reduced and transcription of a large number of genes involved in oxidative stress defense mechanisms was differentially increased. Metabolites involved in the glutathione synthesis pathway (an important antioxidant defense) were also affected but the effects of cadmium were found to be more pronounced at the transcript level than in the metabolome, suggesting that the former exhibits greater sensitivity toward cadmium exposure.
Assuntos
Cádmio/toxicidade , Chlamydomonas reinhardtii/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade , Cádmio/análise , Cromatografia Gasosa-Espectrometria de Massas , Perfilação da Expressão Gênica , Regulação da Expressão Gênica/efeitos dos fármacos , Água/químicaRESUMO
The Krebs cycle plays a fundamental role in cardiac energy production and is often implicated in the energetic imbalance characteristic of heart disease. In this study, we measured Krebs cycle flux in real time in perfused rat hearts using hyperpolarized magnetic resonance spectroscopy (MRS). [2-(13)C]Pyruvate was hyperpolarized and infused into isolated perfused hearts in both healthy and postischemic metabolic states. We followed the enzymatic conversion of pyruvate to lactate, acetylcarnitine, citrate, and glutamate with 1 s temporal resolution. The appearance of (13)C-labeled glutamate was delayed compared with that of other metabolites, indicating that Krebs cycle flux can be measured directly. The production of (13)C-labeled citrate and glutamate was decreased postischemia, as opposed to lactate, which was significantly elevated. These results showed that the control and fluxes of the Krebs cycle in heart disease can be studied using hyperpolarized [2-(13)C]pyruvate.
Assuntos
Ciclo do Ácido Cítrico/fisiologia , Espectroscopia de Ressonância Magnética/métodos , Miocárdio/metabolismo , Acetilcarnitina/metabolismo , Animais , Isótopos de Carbono , Ácido Cítrico/metabolismo , Metabolismo Energético , Ácido Glutâmico/metabolismo , Técnicas In Vitro , Cinética , Ácido Láctico/metabolismo , Masculino , Modelos Cardiovasculares , Isquemia Miocárdica/metabolismo , Perfusão , Ácido Pirúvico/metabolismo , Ratos , Ratos WistarRESUMO
The problem of model detection and parameter estimation for noisy signals arises in different areas of science and engineering including audio processing, seismology, electrical engineering, and NMR spectroscopy. We have adopted the Bayesian modeling framework to jointly detect and estimate signal resonances. This considers a model of the time-domain complex free induction decay (FID) signal as a sum of exponentially damped sinusoidal components. The number of model components and component parameters are considered unknown random variables to be estimated. A Reversible Jump Markov Chain Monte Carlo technique is used to draw samples from the joint posterior distribution on the subspaces of different dimensions. The proposed algorithm has been tested on synthetic data, the (1)H NMR FID of a standard of L-glutamic acid and a blood plasma sample. The detection and estimation performance is compared with Akaike information criterion (AIC), minimum description length (MDL) and the matrix pencil method. The results show the Bayesian algorithm superior in performance especially in difficult cases of detecting low-amplitude and strongly overlapping resonances in noisy signals.